menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Shining a New Light on the tug-of-war Between Virus and Host

ReachMD Healthcare Image
02/01/2024
eurekalert.org

image: 

The HIRI researchers involved in the study; from left: Alexander Gabel, Nora Schmidt, Mathias Munschauer, Jens Aydin, Sabina Ganskih, and Sebastian Zielinski

view more 

Credit: HIRI/Nik Schölzel

When RNA viruses, including the coronavirus SARS-CoV-2, infect our cells, they utilize regulatory RNA elements to recruit proteins of virus and host in order to execute their own gene expression program and enable the production of viral progeny. Understanding the interactions of viral RNAs and the regulatory elements therein is therefore the first step towards identifying vulnerabilities in the viral replication process and facilitating the rational design of novel antivirals.

The method

Researchers from the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg, in collaboration with the Broad Institute of MIT and Harvard in the US, have recently developed a new method that, for the first time, enables the discovery of interactions for specific regions within a target RNA molecule. Using mass spectrometry, the technique, named SHIFTR, allows the unbiased and comprehensive mapping of proteins that interact with a specific RNA sequence—in living cells and without genetic modification.

“Until now, it has not been possible to study the interplay between proteins and individual RNA regions in live cells without genetic manipulation, for instance, by adding tag sequences to the target RNA. Our method, called SHIFTR, finally delivers this and is easy to execute, too. Beyond region-resolution, SHIFTR also requires orders of magnitudes fewer input material compared to the state-of-the-art, is highly scalable and cost-effective,” explains Mathias Munschauer, who leads a research group at the Helmholtz Institute Würzburg, a site of the Braunschweig Helmholtz Centre for Infection Research (HZI) in cooperation with the Julius-Maximilians-Universität (JMU) Würzburg.

“With this new tool we can determine the interactions for practically every cellular RNA and every regulatory element within these RNAs,” says Jens Aydin, a PhD student in Mathias Munschauer's research group and the first author of the study in Nucleic Acids Research. “This can fundamentally change the way we look at RNA in the cell—a crucial milestone,” adds Munschauer.

SARS-CoV-2 in focus

Using the new method, the research team was able to shed further light on the replication process of SARS-CoV-2. The scientists separately examined different sequence regions within authentic SARS-CoV-2 RNAs produced during infection and were able to interrogate the 5’ and 3’ terminal regions of the viral RNA for the first time. These regions are known to contain untranslated regulatory elements that control protein synthesis and RNA stability, as well as the replication of the viral genome. In addition to known interactors, they uncovered previously unknown interactions with proteins linked to the biogenesis of viral RNAs. Some of these newly discovered interactions could serve as targets for innovative antiviral therapies.

In the future, SHIFTR can be harnessed to better understand how cellular transcriptomes, the entirety of RNA molecules in a cell, are regulated in health and disease, which may uncover novel regulatory interdependencies and drug targets. Moreover, researchers can also use the SHIFTR platform to characterize how RNA-based therapeutics interface with the regulatory machinery of the target cell, which could inspire efforts to design optimized RNA-based drugs, such as mRNA vaccines.

Funding

The study was supported by funding from the Helmholtz Young Investigator Group Program, the European Research Council (ERC), and the FOR-COVID Research Network. Nora Schmidt was additionally funded through the EMBO Long-Term Fellowship Program. The Helmholtz Association has provided the funding for the open access charge.

Helmholtz Centre for Infection Research:

Scientists at the Helmholtz Centre for Infection Research (HZI) in Braunschweig and its other sites in Germany are engaged in the study of bacterial and viral infections and the body’s defence mechanisms. They have a profound expertise in natural compound research and its exploitation as a valuable source for novel anti-infectives. As member of the Helmholtz Association and the German Center for Infection Research (DZIF) the HZI performs translational research laying the ground for the development of new treatments and vaccines against infectious diseases. www.helmholtz-hzi.de/en

Helmholtz Institute for RNA-based Infection Research:

The Helmholtz Institute for RNA-based Infection Research (HIRI) is the first institution of its kind worldwide to combine ribonucleic acid (RNA) research with infection biology. Based on novel findings from its strong basic research program, the institute’s long-term goal is to develop innovative therapeutic approaches to better diagnose and treat human infections. HIRI is a site of the Braunschweig Helmholtz Centre for Infection Research (HZI) in cooperation with the Julius-Maximilians-Universität Würzburg (JMU) and is located on the Würzburg Medical Campus. More information at www.helmholtz-hiri.de.



Journal

Nucleic Acids Research

Method of Research

Experimental study

Subject of Research

Cells

Article Title

SHIFTR enables the unbiased identification of proteins bound to specific RNA regions in live cells

Article Publication Date

28-Jan-2024

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Facebook Comments

Schedule28 May 2024